As a developer and manufacturer of veterinary portfolios, why do we believe in innovation?
Because one aspect that makes our products successful is that we are constantly developing them.
We are convinced that every animal has the right to a dignified life, free from pain and suffering. To achieve this goal, we consistently strive to sustainably develop and produce special solutions for animal health that go beyond the scope of generics. While VetViva products, for the most part, are generic veterinary medicines, our product development puts the focus on ‘generic+’:
Unlike pure generics, our products provide an added benefit. For example, by improving the method of administration or the marketing authorisation for additional animal species, by offering alternative pack sizes, shorter withdrawal periods, improved formulations or new indications.
The VetViva development team observes developments in veterinary medicine worldwide with the goal of making a valuable contribution to animal health and supply reliability.
A team of pharmaceutical specialists, veterinarians, and distribution, with the support of our worldwide distribution partners, is focused on the development of new as well as “generic+” products for small and large animals and horses, in selected indications.
Our products provide an added benefit:
Our Regulatory Affairs team coordinates all activities to attain marketing authorisations in over 50 markets worldwide. Our decades of experience with national authorisation procedures extends over several continents, from Australia to Canada. In line with our current focus on the European Union and EU-like markets, we are increasingly concentrating on decentralised and mutual recognition procedures.
New projects for our product portfolio ensure the continuous success of our regulatory activities, whereby we utilise a variety of submission strategies for generic and also for complete applications.
VetViva – First choice in animal health for selected indications:
The in-house VetViva development team pools knowledge about our products and thus guarantees:
Together with our approximately 70 distribution partners worldwide, we strive to satisfy the needs of our customers – veterinarians and their patients – in the best possible way. Long-standing partnerships with our customers worldwide make a valuable contribution to the development of our products. Together, we identify therapeutic needs and thus close existing gaps. Because we care.
The implementation of the highest quality standards and well-founded experience in the field of pharmaceutical technology are indispensable for the safe and efficient production of medicinal products. A quality management system that is continuously monitored and improved is the key factor for consistently high product quality.
Our core competence is the manufacture of sterile and nonsterile solutions. In particular, aqueous injection solutions are among the main forms, along with semisolid products such as suspensions, ointments and ear drops, gels, and powders.
All processes of VetViva Richter GmbH, from the selection of raw material suppliers to the production process and packaging, are subject to strict quality controls and the current GMP specifications.
Meticulous reporting of adverse effects is an important feature of our corporate responsibility. Through the use of electronic reporting systems and simplified reporting procedures, we reliably and continuously review the benefit/risk profile of our products. If you would like to contact us regarding adverse effects, please use our adverse effect report form.
